| Name | Title | Contact Details |
|---|
THE KRONOS GROUP is a Phoenix, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ChartSpan is a healthcare data company serving patients, providers and employers. Consumers use ChartSpan`s Patient Platform to manage their electronic healthcare records and information on their smartphone, tablet or computer. ChartSpan`s iPhone, iPad, Android and Android Tablet apps have all become the #1 most downloaded medical apps in the U.S. Providers (hospitals, clinics and doctors) leverage ChartSpan`s consumer products to deliver world-class patient EaaS (Engagement-as-a-Service™) to their patients. Employers utilize ChartSpan`s consumer products to manage wellness and healthcare analytics within its employee population.
Vericred, Inc. is a healthcare data services company, operating at the intersection of health insurance and technology. Vericred serves companies who are transforming today`s healthcare experience, from care management to finding the right insurance plan. Its datasets are the foundation on which the healthcare industry builds innovative solutions. Vericred`s health insurance data platform, which is comprised of plan design and rate data, provider-network data and formulary data, offers a solution to an industry plagued by highly fragmented, rapidly changing data that currently exists in non-standard and non-structured formats.
PMEB Medical Billing is a Houston, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.